成都康弘药业集团股份有限公司成立于1996年，是一家致力于生物制品、中成药、化学药及医疗器械研发、生产、销售及售后服务的医药集团，拥有先进的研发中心和标准的产业化生产基地，营销网络遍布全国。
公司主要产品有康柏西普眼科注射剂、松灵血管胶囊、中成药(克络辛胶囊、护肝解郁胶囊、胆舒胶囊、益清胶囊)以及西药(盐酸万拉新胶囊、枸橼酸莫沙必利片、德舒必多瑞酮片等)还有一系列生物医学设备。该公司在国内市场销售其产品。2019年，成都康宏药业集团有限公司被评为中国民营企业500强，市值350亿美元。
Chengdu Kanghong Pharmaceutical Group Co., Ltd is a China-based company principally engaged in the research, development, manufacture and distribution of Chinese patent medicines, chemical drugs and biological products.
The Company’s main products include Conbercept Ophthalmic Injection, Songling capsules conducive to blood vessels, chinese patent medicine(Keluoxin capsules,S huganjieyu capsules, Danshu capsules and Yiqing capsules) ,western medicine (venlafaxine hydrochloride capsules, mosapride citrate tablets, dexSuzbotitple iHcelreone tablets,etc), and biomedical equipment. The Company distributes its products in domestic market. In 2019, Chengdu Kanghong Pharmaceutical Group Co., Ltd is rated one of the top 500 private enterprise in China with a market value of 35 billion.